A comprehensive view of Novartis AG. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
Novartis reports 78.8% of multiple sclerosis patients given continuous treatment with injectable drug Kesimpta ofatumumab have no relapse, worsening or condition, disease activity after four years of treatment; Kesimpta had sales of US$195M in Q1
Published:
June 29, 2022
by SeeNews Pharmaceuticals
|
FDA grants accelerated approval for oral Tafinlar dabrafenib and Mekinist trametinib from Novartis to treat unresectable or metastatic solid tumors with BRAF V600E mutation in adult, pediatric patients; BRAF V600E accounts for 90% of BRAF-mutant cancers
Published:
June 27, 2022
by PharmaBiz
|
Health Canada approves Novartis’ Tabrecta capmatinib tablets to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer; NSCLC is most common type of lung cancer, will affect 30,000 Canadians in 2022
Published:
June 09, 2022
by Canada Newswire
|
Novartis seeks to grow contract development, manufacturing unit with 15 biotech, cell, gene facilities in US, Europe, Asia; CDMO unit offers microbial fermentation, container filling, global packaging logistics, viral vector production, other services
Published:
May 17, 2022
by BioPharma-Reporter.com
|
Novartis reports combination of Kisqali ribociclib and fulvestrant offer survival benefit of almost 16 months in previously untreated breast cancer versus fulvestrant alone; Kisqali is approved in more than 95 countries to treat breast cancer
Published:
May 13, 2022
by SeeNews Pharmaceuticals
|
Ask us about our R&D/Patents market view
Trending Chart
Interactive chart with headline count